Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 243

1.

Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.

Tran MA, Smith CD, Kester M, Robertson GP.

Clin Cancer Res. 2008 Jun 1;14(11):3571-81. doi: 10.1158/1078-0432.CCR-07-4881.

2.

Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.

Peng CL, Guo W, Ji T, Ren T, Yang Y, Li DS, Qu HY, Li X, Tang S, Yan TQ, Tang XD.

Cancer Biol Ther. 2009 Sep;8(18):1729-36. Epub 2009 Sep 6.

PMID:
19633425
3.

Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.

Jane EP, Premkumar DR, Pollack IF.

J Pharmacol Exp Ther. 2006 Dec;319(3):1070-80. Epub 2006 Sep 7.

4.

Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.

Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.

J Cell Physiol. 2009 Jul;220(1):214-21. doi: 10.1002/jcp.21753.

PMID:
19288493
5.

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.

Cancer Res. 2006 Dec 15;66(24):11851-8.

6.

Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.

Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW, Tang ZY.

Clin Cancer Res. 2008 Aug 15;14(16):5124-30. doi: 10.1158/1078-0432.CCR-07-4774.

7.

c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition.

Carr BI, Wang Z, Wang M, Cavallini A, D'Alessandro R, Refolo MG.

Cancer Biol Ther. 2011 Sep 15;12(6):531-8. doi: 10.4161/cbt.12.6.16053. Epub 2011 Sep 15.

PMID:
21734462
8.

Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.

Huether A, Höpfner M, Baradari V, Schuppan D, Scherübl H.

Biochem Pharmacol. 2007 May 1;73(9):1308-17. Epub 2007 Jan 5.

PMID:
17266941
9.

Elesclomol, counteracted by Akt survival signaling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells.

Qu Y, Wang J, Sim MS, Liu B, Giuliano A, Barsoum J, Cui X.

Breast Cancer Res Treat. 2010 Jun;121(2):311-21. doi: 10.1007/s10549-009-0470-6. Epub 2009 Jul 16.

PMID:
19609669
10.

Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.

Yu C, Friday BB, Lai JP, Yang L, Sarkaria J, Kay NE, Carter CA, Roberts LR, Kaufmann SH, Adjei AA.

Mol Cancer Ther. 2006 Sep;5(9):2378-87.

11.

Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.

Gollob JA, Wilhelm S, Carter C, Kelley SL.

Semin Oncol. 2006 Aug;33(4):392-406. Review.

PMID:
16890795
12.

A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.

Cohen SM, Mukerji R, Timmermann BN, Samadi AK, Cohen MS.

Am J Surg. 2012 Dec;204(6):895-900; discussion 900-1. doi: 10.1016/j.amjsurg.2012.07.027.

PMID:
23231932
13.

[Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro].

Chen FS, Cui YZ, Luo RC, Wu J, Zhang H.

Nan Fang Yi Ke Da Xue Xue Bao. 2008 Aug;28(9):1684-7. Chinese.

14.

Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells.

Edwards LA, Verreault M, Thiessen B, Dragowska WH, Hu Y, Yeung JH, Dedhar S, Bally MB.

Mol Cancer Ther. 2006 Mar;5(3):645-54.

16.

Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.

Piguet AC, Saar B, Hlushchuk R, St-Pierre MV, McSheehy PM, Radojevic V, Afthinos M, Terracciano L, Djonov V, Dufour JF.

Mol Cancer Ther. 2011 Jun;10(6):1007-17. doi: 10.1158/1535-7163.MCT-10-0666. Epub 2011 Apr 12.

17.

Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines.

Pasqualetti G, Ricciardi S, Mey V, Del Tacca M, Danesi R.

Lung Cancer. 2011 Nov;74(2):197-205. doi: 10.1016/j.lungcan.2011.03.003. Epub 2011 May 6.

PMID:
21529991
18.

AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).

Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC, Thng CH, Chow P, Ong HS, Chung A, Goh BC, Smith PD, Soo KC.

J Hepatol. 2010 Jan;52(1):79-87. doi: 10.1016/j.jhep.2009.10.008. Epub 2009 Oct 28.

PMID:
19910069
20.

The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.

Gedaly R, Angulo P, Chen C, Creasy KT, Spear BT, Hundley J, Daily MF, Shah M, Evers BM.

Anticancer Res. 2012 Jul;32(7):2531-6.

PMID:
22753710

Supplemental Content

Support Center